Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Initial Sales of Bisphosphonate Disappointing
September 23, 2002
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 23, 2002
-
ARCHIVE IFPW General Membership Meeting Held in Monte Carlo
September 23, 2002
-
ARCHIVE REGULATORY NEWS IN BRIEF
September 23, 2002
-
ARCHIVE Banyu to Boost Its Sales to \300 Bil. by FY2007: Mr Nagasaka
September 23, 2002
-
ARCHIVE Cancer Risk Increases with Level of Alcohol Consumption: Korosho Report
September 23, 2002
-
ARCHIVE Korosho Calls For Closer Management of Radiation Devices
September 23, 2002
-
ARCHIVE Makers Called On to Take Measures to Prevent Drug Misuse
September 23, 2002
-
ARCHIVE BI, Pfizer to Start Long-term Clinical Trial for Spiriva
September 23, 2002
-
ARCHIVE Sysmex Doubles Production Capacity
September 23, 2002
-
ARCHIVE Clinical Trials of Imported Drugs Unapproved in Japan to Be Stimulated
September 23, 2002
-
ARCHIVE BULLETIN
September 23, 2002
-
ARCHIVE Package Inserts Revised for Coadministration of Ribavirin, IFN
September 23, 2002
-
ARCHIVE WORLD NEWS IN BRIEF
September 23, 2002
-
ARCHIVE White Paper Focuses on Different Economic Conditions between Generations
September 23, 2002
-
ARCHIVE Ortho Clinical Diagnostics: HCV Antigen Test Kits
September 23, 2002
-
ARCHIVE NEW PRODUCTS
September 23, 2002
-
ARCHIVE Gastric Cancer Discovered in 0.29% of Individuals by Endoscopy
September 23, 2002
-
ARCHIVE Specialization in Niche Market Recommended for Japanese Companies: Dr Bouee
September 23, 2002
-
ARCHIVE Toshiba: New Biochemical Analyzer ARCHITECT c8000
September 23, 2002
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…